Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688152 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03688152 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 9 participants.
The verdict
NCT03688152, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Interventions
- DRUG INCB053914
- DRUG INCB050465
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2020-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03688152
The ClinicalTrials.gov registry entry for NCT03688152 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which INCB053914 is the first listed.
NCT03688152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03688152 about?
NCT03688152 is a clinical study titled "A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma". The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
What is the current status of trial NCT03688152?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2018-12-03. Estimated completion is 2020-09-01.
What interventions are being tested in trial NCT03688152?
The interventions under investigation include: INCB053914 (DRUG), INCB050465 (DRUG).
Who is sponsoring clinical trial NCT03688152?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.